AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-K$LFCR

LIFECORE BIOMEDICAL, INC. \DE\ (LFCR): Entry into a Material Definitive Agreement

LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 24, 2026, Lifecore Biomedical, LLC (“Lifecore”), a subsidiary of Lifecore Biomedical, Inc. (the “Company”), entered into an Amendment No. 3 to Amended and Restated Contract Manufacturing Agreement (the “Third Amen

Event · Contract
Role
supplier
Counterparty
Alcon Research, LLC
Scope
Contract Manufacturing Agreement
Duration
Initial Term ending December 31, 2034

Facts are quoted from the filing text and checked against it.

Original reporting
SEC EDGAR 8-K
Published Sep 29, 2026, 8:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$LFCR
Bullish
medium confidence
Mentioned
$LFCR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$LFCRBullishLow
01

Why it matters

The extension of the agreement provides revenue visibility through 2034, which may be modestly supportive for the stock, though the overall financial impact is limited by the company's size.

02

Market read

A primary disclosure of a contract extension for a micro‑cap biotech supplier; modest relevance for traders focused on small‑cap medical‑device stocks.

03

What to watch

Potential competition from other contract manufacturers and any future regulatory changes affecting ophthalmic devices.

Relevance 6/10Novelty 5/10Timing: effective November 1, 2026

Background

Lifecore Biomedical, a micro‑cap medical‑device supplier, filed an 8‑K to disclose a material amendment to its long‑standing contract with Alcon Research, a subsidiary of a larger ophthalmic firm.

Company-level read

Ticker impact

$LFCRBullishMedium confidence
Context

The company filed an 8‑K reporting a Third Amendment to its contract manufacturing agreement with Alcon, extending the term to 2034 and setting minimum purchase obligations.

Expected impact

likely modest upside as the market prices in the extended contract and purchase commitments

Evidence & confidence

Longer contract term and guaranteed purchases reduce revenue volatility, but the scale is limited for a micro‑cap issuer.

Market effects

Sector

May signal stability in the ophthalmic contract manufacturing niche.

Regional

Limited to U.S. biotech and medical device suppliers.

Global

Low; impact confined to Lifecore and its partner Alcon.

Counterpoint

What could challenge this read

The amendment could lock Lifecore into lower‑margin terms if Alcon's demand weakens.

Key entities

  • company
    Lifecore Biomedical, Inc.

    Issuer of the 8‑K and subject of the contract amendment.

  • company
    Alcon Research, LLC

    Counterparty to the manufacturing agreement.

Read at source← All news

Related articles

$LFCRHigh

Lifecore Biomedical, Inc. entered into an Agreement and Plan of Merger with Lifecore Inc. and Hazel Merger Sub, Inc. providing for the merger of Merger Sub…

LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on September 27, 2026, Lifecore Biomedical, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Lifecore Inc. (“Parent”) and Hazel Merger Sub, Inc. (“Merger Sub”) providing for the merger

SEC EDGAR 8-K
$LFCRMed

Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026, and Provides Corporate Update

LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026 , and Provides Corporate Update -- Multiple New Business Wins Continue to Strengthen Growing Pipeline -- CHASKA, Minn., November 4, 2026 -- Lifecore Biomedical, Inc. (NASDAQ:

SEC EDGAR 8-K
$LFCRMed

Lifecore Biomedical, Inc. entered into an Agreement and Plan of Merger with Lifecore Inc. and Hazel Merger Sub, Inc. On October 16, 2026, the Board of…

LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on September 27, 2026, Lifecore Biomedical, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Lifecore Inc. and Hazel Merger Sub, Inc. On October 16, 2026, the Board of Directors (the “

SEC EDGAR 8-K
$HRLMedAI 8/10

Deal Dispatch: Hormel Acquires Brakebush, Onsemi buys Synaptics for $5.7 Billion, Leslie’s Pools Bankrupt

Hormel (HRL) acquires Brakebush for $1.06B; Onsemi (ON) to buy Synaptics for $5.7B; Leslie's files for bankruptcy. Valley National (VLY) to acquire Bluevine for $340M. Yext (YEXT) to acquire Flamel.ai. Lifecore (LFCR) to be acquired by Webster Equity for up to $663.7M. SoftBank completes DigitalBridge acquisition. GBTG acquired by Long Lake for $6.3B.

benzinga.com